QNCX
Quince TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
QNCX vs peer average
51/100
QNCX vs. peer average (C vs. C)
Grade spread
A 3 · B 2 · D 3 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
PRLD is the first available peer comparator.
Clinical-stage biotech peer useful for benchmarking small-cap biotech financing risk and event-driven valuation swings, though QNCX is now more restructuring-driven than pipeline-driven.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
QNCX
Quince Therapeutics
PRLD
Prelude Therapeutics
Grade
C
A
Momentum
74
85
Value
41
41
Sentiment
50
75
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs PRLD
QNCX / PRLD
Grade Position
In line
QNCX vs. peer average (C vs. C)
51/100
Momentum
74
PRLDValue
41
QNCXSentiment
50
PRLDRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs QNCX
PRLD is the first peer returned for this comparison set.